Nanxin Liu

机构：First Affiliated Hospital of Xi'an Jiaotong University · ORCID：0000-0002-5335-5118

发表论文 13 篇 · 总被引 160 次 · h-index 8

代表论文

• Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization (2021 · Drug Discovery Today · 被引 53)
• The Recent Advance of Cell-Penetrating and Tumor-Targeting Peptides as Drug Delivery Systems Based on Tumor Microenvironment (2023 · Molecular Pharmaceutics · 被引 40)
• Inside-out extracellular vesicles-like biomimetic magnetic nanoparticles for efficient screening P-Glycoprotein inhibitors to overcome cancer multidrug resistance (2023 · Colloids and Surfaces B Biointerfaces · 被引 14)
• Identification of a Putative SARS-CoV-2 Main Protease Inhibitor through In Silico Screening of Self-Designed Molecular Library (2023 · International Journal of Molecular Sciences · 被引 12)
• Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors (2022 · European Journal of Medicinal Chemistry · 被引 10)
• Discovery of selective platelet-derived growth factor receptor-beta (PDGFR-β) bifunctional small-molecule degraders (2022 · Bioorganic & Medicinal Chemistry · 被引 9)